Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
Published 2023 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Immune and pathologic responses in patients with localized prostate cancer who received daratumumab (anti-CD38) or edicotinib (CSF-1R inhibitor)
Authors
Keywords
-
Journal
Journal for ImmunoTherapy of Cancer
Volume 11, Issue 3, Pages e006262
Publisher
BMJ
Online
2023-03-22
DOI
10.1136/jitc-2022-006262
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD38 in Advanced Prostate Cancers
- (2021) Christina Guo et al. EUROPEAN UROLOGY
- ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).
- (2021) Sumit Kumar Subudhi et al. JOURNAL OF CLINICAL ONCOLOGY
- Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial
- (2021) Thierry Facon et al. LANCET ONCOLOGY
- Combined CTLA-4 and PD-L1 blockade in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer is associated with increased myeloid and neutrophil immune subsets in the bone microenvironment
- (2021) Sumit K Subudhi et al. Journal for ImmunoTherapy of Cancer
- Adenosine receptor blockade with ciforadenant +/- atezolizumab in advanced metastatic castration-resistant prostate cancer (mCRPC).
- (2020) Lauren Christine Harshman et al. JOURNAL OF CLINICAL ONCOLOGY
- Single-Cell Analyses Inform Mechanisms of Myeloid-Targeted Therapies in Colon Cancer
- (2020) Lei Zhang et al. CELL
- Daratumumab induces mechanisms of immune activation through CD38+ NK cell targeting
- (2020) Domenico Viola et al. LEUKEMIA
- The adenosine pathway in immuno-oncology
- (2020) Bertrand Allard et al. Nature Reviews Clinical Oncology
- Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials
- (2020) Saad Z Usmani et al. Lancet Haematology
- Immunomodulatory Activity of a Colony-stimulating Factor-1 Receptor Inhibitor in Patients with Advanced Refractory Breast or Prostate Cancer: A Phase I Study
- (2020) Karen A. Autio et al. CLINICAL CANCER RESEARCH
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
- (2020) Jianjun Gao et al. NATURE MEDICINE
- CD38: An Immunomodulatory Molecule in Inflammation and Autoimmunity
- (2020) Zayda L. Piedra-Quintero et al. Frontiers in Immunology
- The immune microenvironment in hormone receptor-positive breast cancer before and after preoperative chemotherapy
- (2019) Adrienne G Waks et al. CLINICAL CANCER RESEARCH
- Daratumumab plus Lenalidomide and Dexamethasone for Untreated Myeloma
- (2019) Thierry Facon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Deletion of a Csf1r enhancer selectively impacts CSF1R expression and development of tissue macrophage populations
- (2019) Rocío Rojo et al. Nature Communications
- Differences in Tumor Microenvironment Dictate T Helper Lineage Polarization and Response to Immune Checkpoint Therapy
- (2019) Shiping Jiao et al. CELL
- Immunomodulatory effects of CD38-targeting antibodies
- (2018) Niels W.C.J. van de Donk IMMUNOLOGY LETTERS
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- IL-23 secreted by myeloid cells drives castration-resistant prostate cancer
- (2018) Arianna Calcinotto et al. NATURE
- Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade
- (2018) Wassim Abida et al. JAMA Oncology
- Effective combinatorial immunotherapy for castration-resistant prostate cancer
- (2017) Xin Lu et al. NATURE
- VISTA is an inhibitory immune checkpoint that is increased after ipilimumab therapy in patients with prostate cancer
- (2017) Jianjun Gao et al. NATURE MEDICINE
- Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade
- (2017) Dung T. Le et al. SCIENCE
- Colony-stimulating factor 1 receptor (CSF1R) inhibitors in cancer therapy
- (2017) Michael A. Cannarile et al. Journal for ImmunoTherapy of Cancer
- Gene expression markers of Tumor Infiltrating Leukocytes
- (2017) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dysfunction of PSA-specific CD8+ T cells in prostate cancer patients correlates with CD38 and Tim-3 expression
- (2015) Alberto Sada Japp et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- An Open-Label, Multicenter, Phase I/II Study of JNJ-40346527, a CSF-1R Inhibitor, in Patients with Relapsed or Refractory Hodgkin Lymphoma
- (2015) B. von Tresckow et al. CLINICAL CANCER RESEARCH
- Results from a Phase IIA Parallel Group Study of JNJ-40346527, an Oral CSF-1R Inhibitor, in Patients with Active Rheumatoid Arthritis despite Disease-modifying Antirheumatic Drug Therapy
- (2015) M. C. Genovese et al. JOURNAL OF RHEUMATOLOGY
- Activated Lymphocyte Recruitment Into the Tumor Microenvironment Following Preoperative Sipuleucel-T for Localized Prostate Cancer
- (2014) Lawrence Fong et al. JNCI-Journal of the National Cancer Institute
- Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
- (2010) B. C. Carthon et al. CLINICAL CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More